Corresponding author: Ruijun CAI, Wujun WANG,.com 【Abstract】 Background and objective Platinum plus a third-generation agent doublet chemotherapy is the standard regimen and rst-line chemotherapy for the treatment of advanced non-small cell lung cancer (NSCLC). e aim of this study is to evaluate the e cacy and safety of docetaxel plus platinum (DP) compared with vinorelbine plus platinum (VP) regimens in patients with advanced NSCLC. Methods We searched the PubMed, EMBASE, Cochrane Library, CNKI, CBM, VIP, and WanFang databases for randomized controlled trials (RCTs), in which DP regimen was compared with VP regimen. No statistical di erences were observed between DP and VP regimens in terms of one-year survival rate, leukopenia, neutropenia, thrombocytopenia, anorexia, nausea, and vomiting.
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肺癌是全球癌症和癌症相关死亡的首要原因，每年 约120万人死于肺癌
[1] 。非小细胞肺癌（non-small cell lung cancer, NSCLC）约占肺癌的80%，其中20%-30%为局部晚 www.lungca.org 
期（III期），40%-50%已有远处转移（IV期）
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